Efficacy of etonogestrel subcutaneous implants versus the levonorgestrel-releasing intrauterine system in the conservative treatment of adenomyosis

Anwen Wei, Xuedong Tang, Wenjuan Yang, Jianqing Zhou, Weili Zhu, Shan Pan
Open medicine (Warsaw, Poland) · 2024 · vol. 19(1) , pp. 20240914 · doi:10.1515/med-2024-0914 · PMID:38584829 · W4393050943
article OA: gold CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study found both etonogestrel implants and levonorgestrel IUDs improved adenomyosis symptoms, but the IUD was more effective for uterine volume reduction and bleeding control with fewer side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Abstract To evaluate the clinical efficacy of etonogestrel subcutaneous implant (ENG-SCI) with that of the levonorgestrel-releasing intrauterine system (LNG-IUD) for adenomyosis treatment. A prospective randomized cohort study was conducted including 108 patients (50 patients in ENG-SCI group and 58 in the LNG-IUD group) with adenomyosis from January 2019 to July 2021. After 3 months of treatment, both ENG-SCI group and LNG-IUD group showed significant improvement in patients’ visual analog scale, pictorial blood loss assessment chart (PBAC), and uterine volume ( P ＜ 0.05). The uterine volume of patients in LNG-IUD group decreased more significantly than that in the ENG-SCI group since 3 months of treatment. The PBAC score in the LNG-IUD group improved better than that in the ENG-SCI group since 6 months of treatment ( P ＜ 0.05). No significant difference in the occurrence rate of ideal vaginal bleeding patterns and the hemoglobin levels between the two groups was observed. The ENG-SCI group had a higher probability of weight gain and progesterone-related side effects ( P ＜ 0.05). Both ENG-SCI and LNG-IUD were effective in treatment of adenomyosis. However, LNG-IUD had a more significant effect in treating adenomyosis-related dysmenorrhea, excessive menstrual flow, anemia, and uterine enlargement, with relatively fewer side effects.

My notes (saved in your browser only)

Condition tags

adenomyosisdysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

SciLite annotations

chemicals 34
etonogestrel levonorgestrel etonogestrel levonorgestrel progesterone levonorgestrel progesterone levonorgestrel progesterone etonogestrel progesterone progesterone etonogestrel estradiol etonogestrel etonogestrel levonorgestrel progesterone progesterone progesterone progesterone estrogen levonorgestrel danazol etonogestrel etonogestrel etonogestrel progestin prostaglandin estrogen thromboxane a2 prostaglandin i2 progestin etonogestrel
organisms 2
noordeloos 2009062 noordeloos 2009062

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T16:23:13.998983+00:00
pubmed
last seen: 2026-05-29T00:32:44.983282+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0 · commercial use OK